On December 14, Nuochengjianhua announced that the novel BTK inhibitor obutinib independently developed by the company reached the main end in phase IIb clinical studies to treat systemic lupus erythematosus, and was also approved by the Drug Evaluation Center of the China Drug Administration to carry out phase III registered clinical trials.

On December 14, Nuochengjianhua announced that the novel BTK inhibitor obutinib independently developed by the company reached the main end in phase IIb clinical studies to treat systemic lupus erythematosus, and was also approved by the Drug Evaluation Center of the China Drug Administration to carry out phase III registered clinical trials.